Dr. “Larry” Frelinger is Director of the Center for Platelet Research Studies and Assistant Professor of Pediatrics at Harvard Medical School. Dr. Frelinger received his Ph.D. from Case Western Reserve University and did post-doctoral fellowships in the Department of Neurology at CWRU and at Scripps Clinic and Research Foundation in La Jolla, California. Dr. Frelinger worked in the Biotech industry between 1990 and 1998, first at Biogen and later at Accumetrics where he played important roles in the development of the Verify-Now point-of-care platelet aggregation device and clinical trial leading to its approval. In 1998 Dr. Frelinger re-entered academia, joining the faculty UMass Medical School as Assistant Professor and Associate Director of the Center for Platelet Function Studies, under the mentorship of Dr. Alan Michelson. At UMass, Dr. Frelinger’s research focused on heterogeneity of response to anti-platelet therapy, or what is sometimes termed aspirin resistance or clopidogrel resistance. After coming to BCH in 2009, Dr. Frelinger’s work contributed to guidelines on the use of proton pump inhibitors with clopidogrel, and identified platelet markers associated with VOCs in patients with sickle cell disease and with bleeding severity in pediatric patients with ITP or with severe hemophilia A. Dr. Frelinger’s recent work is focused on the role of platelet subsets, identified by spectral flow cytometry, in health and disease.
Dr. Frelinger is a past Co-Chair of the Platelet Physiology Scientific Subcommittee of the International Society on Thrombosis and Haemostasis and has served as an Editor for Scientific Reports and the journal Platelets. Dr. Frelinger was a contributor to the first three editions of the book Platelets and is Associate Editor of the 4th edition. Dr. Frelinger has published more than 120 peer-reviewed original research articles and is an inventor on three awarded and three provisional U.S. patents.
Publications
Clinical and research methods for analysis and study of platelet populations. Blood. 2025 Dec 11; 146(24):2889-2901. View Abstract
A minimum valency of 4 is required for robust activation of platelets in flow cytometry by multivalent nanobodies to Glycoprotein VI, C-type lectin-like receptor 2 and Platelet Endothelial Aggregation Receptor 1. Res Pract Thromb Haemost. 2025 Oct; 9(7):103196. View Abstract
Association of microtubule destabilization with platelet yields in terminally differentiating hiPSC-derived megakaryocyte lines. PLoS One. 2025; 20(6):e0326165. View Abstract
Protocol for assessing and visualizing cell microaggregate formation in whole blood by imaging flow cytometry. STAR Protoc. 2025 Mar 21; 6(1):103598. View Abstract
Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. 2023 10 12; 142(15):1281-1296. View Abstract
OMIP-097: High-parameter phenotyping of human platelets by spectral flow cytometry. Cytometry A. 2023 12; 103(12):935-940. View Abstract
Clinical Cytometry for Platelets and Platelet Disorders. Clin Lab Med. 2023 09; 43(3):445-454. View Abstract
Platelet Phenotyping by Full Spectrum Flow Cytometry. Curr Protoc. 2023 Feb; 3(2):e687. View Abstract
Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2022 09; 20(9):2127-2135. View Abstract
Comprehensive phenotyping of human platelets by single-cell cytometry. Cytometry A. 2022 04; 101(4):290-297. View Abstract
Comparison and Analysis of Gut Microbiota in Children With IgA Vasculitis With Different Clinical Symptoms. Front Pediatr. 2021; 9:800677. View Abstract
Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia. Immunity. 2022 02 08; 55(2):224-236.e5. View Abstract
Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. Atherosclerosis. 2021 12; 339:12-19. View Abstract
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease. Thromb Haemost. 2022 06; 122(6):951-960. View Abstract
Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2021 12; 19(12):3193-3202. View Abstract
Immunophenotypic Analysis of Platelets by Flow Cytometry. Curr Protoc. 2021 Jun; 1(6):e178. View Abstract
Platelet Immunophenotyping by High-Dimensional Mass Cytometry. Curr Protoc. 2021 May; 1(5):e112. View Abstract
Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin. PLoS One. 2021; 16(4):e0249209. View Abstract
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. Blood. 2021 04 15; 137(15):2010-2020. View Abstract
Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681. View Abstract
Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. J Thromb Haemost. 2021 04; 19(4):976-982. View Abstract
Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters. Cytometry A. 2021 02; 99(2):170-179. View Abstract
Platelet surface GPIba, activated GPIIb-IIIa, and P-selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients. Platelets. 2022 Jan 02; 33(1):116-122. View Abstract
Platelet count and disease - editorial policy. Platelets. 2020 Nov 16; 31(8):969-970. View Abstract
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2020 04; 63(4):733-743. View Abstract
Platelet surface marker analysis by mass cytometry. Platelets. 2020 Jul 03; 31(5):633-640. View Abstract
Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. Med Hypotheses. 2019 Apr; 125:100-105. View Abstract
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study. Clin Transl Sci. 2019 03; 12(2):180-188. View Abstract
Publisher Correction: GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 Nov 29; 8(1):17580. View Abstract
Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018 12; 16(12):2515-2519. View Abstract
Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2018 11; 16(11):2341-2346. View Abstract
GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 09 28; 8(1):14529. View Abstract
Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology. PLoS One. 2018; 13(9):e0203557. View Abstract
Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia. Sci Rep. 2018 07 09; 8(1):10300. View Abstract
Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost. 2018 Jul; 2(3):439-449. View Abstract
Using flow cytometry to monitor glycoprotein IIb-IIIa activation. Platelets. 2018 Nov; 29(7):670-676. View Abstract
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply. J Thromb Haemost. 2018 03; 16(3):607-608. View Abstract
Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity. Thromb Haemost. 2018 01; 118(1):143-151. View Abstract
Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease. Thromb Res. 2017 Dec; 160:58-65. View Abstract
High serum serotonin in sudden infant death syndrome. Proc Natl Acad Sci U S A. 2017 07 18; 114(29):7695-7700. View Abstract
Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis? J Am Coll Cardiol. 2017 06 13; 69(23):2879. View Abstract
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. J Thromb Haemost. 2017 05; 15(5):858-867. View Abstract
Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017 Feb 14; 69(6):603-612. View Abstract
Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma. PLoS One. 2016; 11(8):e0160933. View Abstract
Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. Biomed Microdevices. 2016 08; 18(4):73. View Abstract
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 07 04; 116(1):69-77. View Abstract
Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):501-9. View Abstract
In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets. 2016 Jun; 27(4):308-16. View Abstract
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2016 Jan 01; 107:204-18. View Abstract
Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets. 2016; 27(3):196-202. View Abstract
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015 Sep 10; 126(11):1367-78. View Abstract
Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9. View Abstract
Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation. Platelets. 2016; 27(2):128-35. View Abstract
A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. Thromb Haemost. 2015 Jul; 114(1):14-25. View Abstract
Platelet activation using electric pulse stimulation: growth factor profile and clinical implications. J Trauma Acute Care Surg. 2014 Sep; 77(3 Suppl 2):S94-S100. View Abstract
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 2015; 26(5):474-9. View Abstract
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014 Jul 29; 64(4):361-8. View Abstract
Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome? Int J Lab Hematol. 2015 Feb; 37(1):112-9. View Abstract
Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'?-P¹ ,P4-dithio-P²,P³-chloromethylenetetraphosphate. PLoS One. 2014; 9(4):e94780. View Abstract
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014 Feb; 133(2):190-5. View Abstract
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol. 2013; 130(3):181-7. View Abstract
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol. 2013 Jun; 75(6):1433-44. View Abstract
The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood. 2013 Jul 18; 122(3):376-85. View Abstract
P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc. 2013 May 15; 2(3):e000026. View Abstract
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal. J Thromb Haemost. 2013 May; 11(5):1002-3. View Abstract
Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35. View Abstract
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013 Feb 17; 6:17. View Abstract
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26; 61(8):872-9. View Abstract
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost. 2013 Feb; 109(2):347-55. View Abstract
Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost. 2012 Dec; 10(12):2573-80. View Abstract
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 03; 59(14):1304-11. View Abstract
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26; 119(17):4066-72. View Abstract
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23; 306(20):2221-8. View Abstract
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost. 2011 Nov; 9(11):2302-10. View Abstract
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One. 2011; 6(9):e24549. View Abstract
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26. View Abstract
Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost. 2011 May; 9(5):1020-8. View Abstract
The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. J Clin Sleep Med. 2011 Apr 15; 7(2):172-8. View Abstract
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011 Apr; 32(7):838-46. View Abstract
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010 Sep 21; 56(13):1017-23. View Abstract
The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv. 2010 Oct; 3(5):442-9. View Abstract
Platelet reactivity with prolonged aspirin treatment--steady going at 2 year. Circ J. 2010 Jun; 74(6):1077-8. View Abstract
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets. 2010; 21(7):525-32. View Abstract
Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009 Dec 22; 120(25):2586-96. View Abstract
Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res. 2010 Feb; 125(2):159-65. View Abstract
Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost. 2010 Feb; 8(2):331-40. View Abstract
Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009 Nov; 20(7):513-9. View Abstract
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63. View Abstract
The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. Thromb Res. 2009 May; 124(1):42-5. View Abstract
Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008 Dec; 6(12):2035-44. View Abstract
Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol. 2008 Jun 15; 123(3-4):345-52. View Abstract
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32. View Abstract
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost. 2008 02; 6(2):359-65. View Abstract
Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. Thromb Res. 2008; 121(5):689-98. View Abstract
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007 Jul; 98(1):192-200. View Abstract
Cystic fibrosis heterozygotes do not have increased platelet activation. Thromb Res. 2007; 121(2):159-62. View Abstract
Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007 Apr; 5(4):761-5. View Abstract
Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007; 120(3):323-36. View Abstract
Current options in platelet function testing. Am J Cardiol. 2006 Nov 20; 98(10A):4N-10N. View Abstract
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost. 2007 Jan; 5(1):75-81. View Abstract
Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. J Thromb Haemost. 2006 Dec; 4(12):2670-7. View Abstract
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006 Jun 27; 113(25):2888-96. View Abstract
Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost. 2005 Nov; 3(11):2563-70. View Abstract
Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol. 2005 Aug 16; 46(4):646-7. View Abstract
Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635-41. View Abstract
Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004 Jun 16; 43(12):2319-25. View Abstract
Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. Am J Cardiol. 2003 Nov 01; 92(9):1099-101. View Abstract
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. J Vasc Surg. 2003 Feb; 37(2):440-5. View Abstract
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Am Heart J. 2003 Feb; 145(2):e6. View Abstract
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002 Jun; 87(6):1020-5. View Abstract
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J. 2001 Nov; 142(5):790-8. View Abstract
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001 Oct; 38(4):1002-6. View Abstract
Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001 Sep 18; 104(12):1374-9. View Abstract
Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion. Cytometry. 2001 Apr 01; 43(4):308-13. View Abstract
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost. 2000 Sep; 84(3):492-8. View Abstract
Evaluation of platelet function by flow cytometry. Methods. 2000 Jul; 21(3):259-70. View Abstract
Progress in point-of-care laboratory testing for assessing platelet function. Am Heart J. 1998 Oct; 136(4 Pt 2 Su):S51-65. View Abstract
Novel methods for assessing platelet function. Am Heart J. 1998 May; 135(5 Pt 2 Su):S184-6. View Abstract
Prevention of experimental carotid artery thrombosis by applaggin. J Pharmacol Exp Ther. 1993 Nov; 267(2):809-14. View Abstract
Arg-Gly-Asp-dependent occupancy of GPIIb/IIIa by applaggin: evidence for internalization and cycling of a platelet integrin. Blood. 1993 Jan 01; 81(1):62-9. View Abstract
A spontaneous mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J Biol Chem. 1992 Feb 25; 267(6):3789-94. View Abstract
Localization of a PlA1 epitope to the amino terminal 66 residues of platelet glycoprotein IIIa. Blood. 1992 Feb 01; 79(3):559-62. View Abstract
Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem. 1991 Sep 15; 266(26):17106-11. View Abstract
Activation of the fibrinogen receptor on human platelets exposed to alpha chymotrypsin. Relationship with a major proteolytic cleavage at the carboxyterminus of the membrane glycoprotein IIb heavy chain. Eur J Biochem. 1991 Sep 01; 200(2):437-47. View Abstract
Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood. 1990 Nov 15; 76(10):2017-23. View Abstract
A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science. 1990 Aug 24; 249(4971):915-8. View Abstract
Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem. 1990 Apr 15; 265(11):6346-52. View Abstract
Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem. 1989 Mar 05; 264(7):3742-9. View Abstract
Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem. 1988 Sep 05; 263(25):12397-402. View Abstract
Molecular cloning and chemical synthesis of a region of platelet glycoprotein IIb involved in adhesive function. Proc Natl Acad Sci U S A. 1987 Oct; 84(20):7114-8. View Abstract
Topography of N-CAM structural and functional determinants. I. Classification of monoclonal antibody epitopes. J Cell Biol. 1986 Nov; 103(5):1721-7. View Abstract
Topography of N-CAM structural and functional determinants. II. Placement of monoclonal antibody epitopes. J Cell Biol. 1986 Nov; 103(5):1729-37. View Abstract
The role of the methionine residues in the structure and function of parathyroid hormone. Arch Biochem Biophys. 1986 Feb 01; 244(2):641-9. View Abstract
Oxidized forms of parathyroid hormone with biological activity. Separation and characterization of hormone forms oxidized at methionine 8 and methionine 18. J Biol Chem. 1984 May 10; 259(9):5507-13. View Abstract
Specific cleavage of bovine parathyroid hormone catalyzed by an endopeptidase from bovine kidney. J Biol Chem. 1981 Nov 25; 256(22):11483-8. View Abstract
Tumor growth and calcitonin during serial transplantation of rat medullary thyroid carcinoma. Endocrinology. 1979 Jul; 105(1):27-32. View Abstract
Plasma immunoreactive calcitonin in lung cancer. Endocr Res Commun. 1979; 6(2):169-90. View Abstract
Acute and chronic fluctuations of immunoreactive and biologically active plasma calcitonin in the rat. Endocrinology. 1978 Dec; 103(6):2180-6. View Abstract
